Thomas Bartl (@thomasbartlmd) 's Twitter Profile
Thomas Bartl

@thomasbartlmd

Gynecogic Oncologist・Junior Faculty @MedUni_Wien ・Editorial Fellow @IJGConline

ID: 1875490174060101632

calendar_today04-01-2025 10:31:25

9 Tweet

43 Followers

64 Following

Manel Montesinos-Albert (@mmontesinos_alb) 's Twitter Profile Photo

Thank you so much for the warm welcome! I am very excited to contribute to impactful research, collaborate with such an inspiring group, and learn from the incredible IJGC community. I look forward to growing together and making a difference! #EditorialFellows #IJGC

IJGC (@ijgconline) 's Twitter Profile Photo

Excited to have Thomas Bartl join the inaugural cohort of #IJGC #EditorialFellows for #2025! 🎉 Beginning his #ESGO Fellowship at the Medical University of #Vienna, Dr. Bartl brings incredible expertise and passion to the team!👥 Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj

Excited to have <a href="/thomasbartlMD/">Thomas Bartl</a> join the inaugural cohort of #IJGC #EditorialFellows for #2025! 🎉 
Beginning his #ESGO Fellowship at the Medical University of #Vienna, Dr. Bartl brings incredible expertise and passion to the team!👥 

<a href="/pedroramirezMD/">Pedro T Ramirez</a> <a href="/HsuMd/">Arthur_HC_Hsu</a> <a href="/JayrajAarthi/">Aarthi S Jayraj</a>
Thomas Bartl (@thomasbartlmd) 's Twitter Profile Photo

🚩Every third physician treating gynecologic cancer patients lacks confidence in managing checkpoint inhibitor side effects, underscoring the need for more specialized training and stronger interdisciplinary collaboration. #gynonc #oncoalert AGO Austria doi.org/10.1186/s12885…

IJGC (@ijgconline) 's Twitter Profile Photo

🌟 #IJGCconversations 🌟 Our EIC, Pedro T Ramirez, had an incredible discussion with the IJGC Fellows about the #2025SpecialIssue topic: Rare Gynecologic Cancers 🎙️💡 Don’t miss this insightful conversation on the latest research and advancements in the field! 🔬✨ 🎧

Thomas Bartl (@thomasbartlmd) 's Twitter Profile Photo

The low incidence of mucinous ovarian cancer continues to hinder both clinical and translational research. Prognosis remains unchanged for decades—with no Phase III trials in sight. It's time to shift the paradigm and drive progress!

ESGO (@esgo_society) 's Twitter Profile Photo

🗣️ ICYMI: This week we learned The International Journal of Gynecological Cancer’s impact factor rose to 4.7! 📈 Congratulations to Pedro Ramirez, the editor-in-chief and his great team of editors! 💐 The IJGC is a joint project of ESGO & IGCS 👉 …l-journal-of-gynecological-cancer.com

🗣️ ICYMI: This week we learned The International Journal of Gynecological Cancer’s impact factor rose to 4.7! 📈 Congratulations to Pedro Ramirez, the editor-in-chief and his great team of editors! 💐

The IJGC is a joint project of ESGO &amp; IGCS 👉 …l-journal-of-gynecological-cancer.com